We are highly experienced in performing evaluation studies of new diagnostic methods and diagnostic clinical trials.
Recently completed clinical trials for which data are published include assessment of the performance of Saliva versus Nasopharyngeal Swabs Specimens for Diagnosis of SARS-CoV-2 by RT-qPCR (Abbott M2000 and Abbott Alinity m Systems; Comparison of Nasal Swabs to Nasal Pharyngeal Swab Specimens for Diagnosis of SARS-CoV-2; and First Published Performance Evaluation of Performance of 3-D Printed Nasopharyngeal Swabs for Diagnosis of SARS-CoV-2. See "Publications" menu for details.
Please contact us if interested in collaboration: Stefan Riedel, MD, PhD: sriedel@bidmc.harvard.edu or James Kirby, MD: jekirby@bidmc.harvard.edu and indicate that you were referred from our website.
Recently completed clinical trials for which data are published include assessment of the performance of Saliva versus Nasopharyngeal Swabs Specimens for Diagnosis of SARS-CoV-2 by RT-qPCR (Abbott M2000 and Abbott Alinity m Systems; Comparison of Nasal Swabs to Nasal Pharyngeal Swab Specimens for Diagnosis of SARS-CoV-2; and First Published Performance Evaluation of Performance of 3-D Printed Nasopharyngeal Swabs for Diagnosis of SARS-CoV-2. See "Publications" menu for details.
Please contact us if interested in collaboration: Stefan Riedel, MD, PhD: sriedel@bidmc.harvard.edu or James Kirby, MD: jekirby@bidmc.harvard.edu and indicate that you were referred from our website.
We develop and provide contemporaneous bacterial strains sets for evaluation of new antimicrobials for the pharmaceutical industry. We are also interested in testing new antimicrobials against our collections in house. If interested in collaboration, please contact: Stefan Riedel, MD, PhD: sriedel@bidmc.harvard.edu and indicate that you were referred from our website.